Eric Hoffman

Co-founder, CEO

Dr. Hoffman received his PhD in Drosophila genetics at Johns Hopkins University, then began working on Duchenne muscular dystrophy as a post-doctoral fellow with Dr. Louis Kunkel at Boston Children’s Hospital and Harvard Medical School.  He has held faculty positions at the University of Pittsburgh School of Medicine, George Washington University, and is currently Professor of Pharmaceutical Sciences and Associate Dean for Research at the School of Pharmacy and Pharmaceutical Sciences at Binghamton University – State University of New York.  

While serving as Director of Research Center for Genetic Medicine at Children’s National Medical Center (1990-2016), Dr. Hoffman established infrastructure for translational research in neuromuscular disease, including founding the Cooperative International Neuromuscular Research Group (CINRG;, and co-founded three companies that spun off from these efforts (TRiNDS LLC [], ReveraGen BioPharma [], and AGADA BioPharma).   Dr. Hoffman’s published research work can be found here.

Dr. Hoffman took on the CEO role from Dr. Nagaraju in 2022, as Dr. Nagaraju became Dean of the School of Pharmacy and Pharmaceutical Sciences at Binghamton University, State University of New York. Dr. Hoffman oversees all operations at AGADA, with a particular focus on clinical trial support (trial design, endpoints, muscle biopsy procedures and methods, and biomarker outcomes).  He works with clients and the expert AGADA team on a day-to-day basis, providing guidance, consulting, data interpretation and sign off on all clinical studies.

Dr. Hoffman has extensive experience with nuances of placement of biomarkers in drug development programs (context of use), ensuring that biomarker assays are appropriate as outcomes in trials (fit for purpose), as well as deep knowledge of the technical aspects of muscle biopsies and data interpretation.  He brings this knowledge and experience to client projects and trials to help ensure robust data in support of regulatory programs.